California Insurance Commissioner Dave Jones said the proposed merger would have significant anticompetitive effects in Medicare Part D, pharmacy benefit manager services and retail pharmacy markets. The lack of competition would lead to higher costs for millions of consumers, he said.
“A merger of this size and type, according to experts on health insurer and healthcare mergers, will likely lead to increased prices and decreased quality,” Mr. Jones said. “Traditional methods to avoid market concentration will not address potential impacts on service quality, the power to charge excessive rates, or the creation of barriers to block a potential market participant with the resources to enter into new markets.”
Mr. Jones made his recommendation after analyzing testimony from a June 19 public hearing, including information from CVS and Aetna executives, provider groups, and healthcare academics.
Mr. Jones said if CVS absorbs Aetna, “an important potential competitor in the PBM market” will disappear. However, the companies have said the deal will provide localized, community-based care across CVS Health’s 9,700-plus pharmacies and 1,100 clinics. Sources familiar with the deal told Reuters in December that CVS Health plans to significantly extend health services at its pharmacies under the merger.
More articles on payers:
Humana posts $193M profit, eyes expansion of Walmart relationship
50K BCBS members to lose in-network access to Duke Health, WakeMed
Trump administration releases final rule for short-term health plans: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.